We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Improvement of White Matter Changes on Neuroimaging Modalities After Stem Cell Transplant in Metachromatic Leukodystrophy

Martje E. van Egmond, MD; Petra J. W. Pouwels, PhD; Jaap-Jan Boelens, MD, PhD; Caroline A. Lindemans, MD, PhD; Frederik Barkhof, MD, PhD; Martijn D. Steenwijk, MSc; Peter M. van Hasselt, MD, PhD; Marjo S. van der Knaap, MD, PhD; Nicole I. Wolf, MD, PhD
JAMA Neurol. 2013;70(6):779-782. doi:10.1001/jamaneurol.2013.629.
Text Size: A A A
Published online

Importance We sought to illustrate improvement of cerebral white matter changes in metachromatic leukodystrophy after treatment with hematopoietic stem cell transplant (HSCT).

Observations We conducted serial magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (1H-MRS) as standard follow-up after HSCT with cord blood in 1 patient with juvenile metachromatic leukodystrophy diagnosed before frank degenerative symptoms developed. We measured MRI and 1H-MRS changes. The white matter changes first increased after HSCT, then decreased in relation to the pre-HSCT MRI and 1H-MRS.

Conclusions and Relevance Hematopoietic stem cell transplant, if performed early in metachromatic leukodystrophy, can not only stabilize but even improve cerebral white matter abnormalities. Our findings suggest a biological effect of HSCT.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal


Place holder to copy figure label and caption
Graphic Jump Location

Figure. Magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (1H-MRS) before and 6, 18, and 27 months after hematopoietic stem cell transplant (HSCT). A-C, Transverse T2-weighted MRI of the brain at 1.5 T (repetition/echo times, 2450/85 ms) before HSCT. Symmetrical periventricular and deep white matter hyperintensities are noted, especially in the frontal regions on both sides, with abnormal signal intensity in the genu of the corpus callosum. Temporal periventricular abnormalities are seen. D-F, Follow-up T2-weighted MRI 6 months after HSCT shows progression of white matter abnormalities, especially in the parietal regions, with ventricular widening. G-I, Follow-up MRI 18 months after HSCT shows significant improvement of the white matter abnormalities, especially in the centrum semiovale in both hemispheres. The temporal periventricular white matter has normalized. J-L, Follow-up MRI 27 months after HSCT shows stable signal abnormalities. M-U, Proton MRS scans were obtained with chemical shift imaging (CSI) (point-resolved spectroscopy sequence; repetition/echo times, 3000/30 ms) just above the corpus callosum. The color maps corresponding to the volume of interest indicated in white on the MRI obtained at the same time represent the concentration ratios of choline-containing compounds to N -acetylaspartate (Cho:NAA) and myo -inositol to NAA (Ins:NAA), as quantified with LCModel (http://s-provencher.com/pages/lcmodel.shtml), which are sensitive markers for disease stage. (For comparison, the mean Cho:NAA and Ins:NAA ratios in normal white matter of adolescents are 0.19 [SD, 0.02] and 0.39 [0.05], respectively). Original spectra data are localized in the yellow square on the MRI obtained at the same time. M-O, Proton MRS obtained before HSCT. P-R, Follow-up 1H-MRS 18 months after HSCT. S-U, Follow-up 1H-MRS 27 months after HSCT. At 6 months after transplant, the patient had moved during the examination, making it impossible to compare the CSI results. Cr indicates creatine.




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics